FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate

The regulator’s restrictions come as the U.S. is experiencing a surge in cases. Invivyd also announced updated Phase III data for Pemgarda, touting an 84% relative reduction in symptomatic COVID-19.